CNBX Pharmaceuticals Inc. \(CNBX\) — Company Breakdown

Executive Summary

CNBX Pharmaceuticals Inc\. \(formerly Cannabics Pharmaceuticals Inc\.\) is a Nevada\-incorporated, Bethesda, Maryland\-headquartered clinical\-stage biopharmaceutical company developing cannabinoid\-based therapeutics for oncology indications\. The company traces its corporate history back to an oil and gas exploration shell that pivoted to biotechnology around 2014, and it has generated no meaningful revenue since\. CNBX conducts its research and development through a government\-licensed facility in Israel and is pursuing an FDA Investigational New Drug \(IND\) pathway for its lead candidates, the most advanced of which target cancer\-related anorexia\-cachexia and colorectal cancer\. The company is extremely small \(effectively a single\-employee operation\), trades on the OTC market at a fraction of a cent per share, and its independent auditors have issued a going\-concern qualification\. CNBX is a legitimate, SEC\-reporting operating company with disclosed R\&D activity, patent filings, and peer\-reviewed pilot data, but it remains pre\-revenue, thinly capitalized, and highly dependent on continued external financing to survive, let alone to reach commercialization.

1\. Core Business Model & How They Work

CNBX operates as a drug\-development shell rather than a manufacturer or marketer of finished products\. Its model rests on three pillars: \(1\) discovering and formulating cannabinoid compounds and combinations with potential anti\-cancer or palliative activity; \(2\) advancing those candidates through preclinical studies and, eventually, Phase I/II human trials under an FDA IND; and \(3\) out\-licensing or partnering successful candidates to larger pharmaceutical companies that have the capital and commercial infrastructure to complete late\-stage trials and bring a product to market\. The company does not own manufacturing capacity; Chemistry, Manufacturing, and Controls \(CMC\) work is contracted out to GMP\-certified suppliers such as Purisys\. Research is centered on a licensed Israeli laboratory, which allows CNBX to work with cannabinoid compounds under a regulatory framework more permissive than the current U\.S\. federal Schedule I classification.

Key Operational Drivers

\- Access to capital: the company's ability to fund preclinical work and eventually clinical trials is the single most important driver of whether the pipeline advances at all\. \- Completion of preclinical safety/toxicology studies, targeted for roughly the third quarter of calendar 2026, which are prerequisites to filing an IND and starting human trials\. \- Initiation of Phase I/II trials, contingent on financing an estimated \$6\.5 million program that was unfunded as of the filing date\. \- Growth and defense of the patent portfolio around its sustained\-release formulation technology and specific cannabinoid combinations\. \- Relationships with contract research organizations, clinical trial sites, and its scientific advisory board, which substitute for in\-house headcount \(the company reported essentially one employee as of its fiscal year\-end\)\. \- Regulatory developments affecting cannabinoid\-derived pharmaceuticals, including any change in DEA scheduling or FDA guidance specific to cannabis\-based drugs.

2\. Business Segments

CNBX operates as a single reportable segment: oncology\-focused cannabinoid drug development\. It does not break out geographic or product segments, so no segment table is presented.

3\. Product Portfolio

| Candidate | Indication / Use | Stage | Notes | \|---|---|---|---| | Cannabics SR | Cancer\-related anorexia\-cachexia syndrome \(CACS\) | Pilot clinical data reported | Sustained\-release oral capsule; pilot study reported weight gains of 10% or more in roughly 17\.6% of patients | | RCC\-33 | Colorectal cancer | Preclinical | Oral capsule combining CBDV and CBGA cannabinoids; preclinical work reported greater than 30% tumor volume reduction | | PLP\-33 | Lateral spreading colorectal polyps | Early\-stage / discovery | Part of the broader "\-33" oncology cannabinoid series | | BRST\-33 | Breast cancer | Early\-stage / discovery | Early pipeline candidate | | MLN\-33 | Melanoma | Early\-stage / discovery | Early pipeline candidate | | PRST\-33 | Prostate cancer | Early\-stage / discovery | Early pipeline candidate | | Cannabics CDx | Companion diagnostic / drug\-sensitivity test | Early\-stage | Intended to help match cannabinoid combinations to individual tumor sensitivity profiles |

None of these candidates has received FDA approval or generated commercial revenue; all remain in preclinical or early pilot stages.

4\. Competitive Landscape

CNBX competes against a mix of larger, better\-capitalized cannabinoid\-focused drug developers and the broader oncology\-therapeutics industry. Named competitors in its own disclosures include GW Pharmaceuticals PLC \(the Epidiolex developer, now part of Jazz Pharmaceuticals\), InMed Pharmaceuticals Inc\., Corbus Pharmaceuticals Holdings Inc\., and Zynerba Pharmaceuticals Inc\., alongside a growing field of emerging cannabis\-focused biotech firms and, more broadly, every oncology\-supportive\-care and targeted\-therapy company addressing cachexia, colorectal cancer, breast cancer, melanoma, and prostate cancer. The company explicitly acknowledges that its competitors generally possess far greater financial, scientific, technical, and intellectual\-property resources, as well as more developed manufacturing, regulatory, and commercial infrastructure. CNBX's only realistic competitive positioning is as a small, focused originator of specific cannabinoid formulations and combinations that a larger partner might license once early clinical signals de\-risk the science — it is not positioned to compete head\-to\-head on scale, funding, or speed to market.

5\. Strategic Strengths & Risks

Competitive Strengths \(The Moat\)

CNBX's moat is thin and mostly optionality\-based rather than structural\. Its most defensible assets are: a patent\-pending sustained\-release oral formulation technology for cannabinoids; early, peer\-reviewed pilot clinical data in cancer anorexia\-cachexia that gives it a small evidentiary head start versus purely preclinical competitors; a reasonably differentiated and focused oncology pipeline built around specific cannabinoid combinations \(such as CBDV plus CBGA for colorectal cancer\) that are not widely replicated elsewhere; and a scientific advisory board with relevant gastroenterology and oncology expertise. The company also benefits from a lower\-cost, government\-licensed Israeli research environment that allows cannabinoid work difficult to conduct as cheaply under U\.S\. federal scheduling. None of these amount to a durable competitive advantage in the traditional sense — there is no brand, no distribution network, no switching cost, no scale, and no pricing power — but the intellectual property and early data are real, filed, and disclosed assets rather than merely aspirational claims.

Strategic Risks & Vulnerabilities

The risk profile is severe and multi\-layered\. The independent auditors have issued a going\-concern qualification, and the company's own filings disclose cumulative losses since inception of over \$25 million against a balance sheet with only a few thousand dollars of cash. CNBX has generated no meaningful revenue since 2014 and has no sales, marketing, or commercial infrastructure of any kind. It is almost entirely dependent on raising additional external financing — likely through dilutive equity issuances given roughly 554 million shares already outstanding and a stock price near \$0\.0076 — simply to keep operating, let alone to fund the estimated \$6\.5 million Phase I/II program that remains unfunded\. The company itself notes that clinical evidence for cannabinoids in cancer treatment remains "preliminary and limited" per National Academies review, meaning the underlying science is unproven at a rigorous clinical level\. Federal Schedule I classification of cannabis\-derived compounds continues to create regulatory uncertainty that could complicate U\.S\. trial execution and eventual commercialization\. Operationally, the company reported essentially one employee as of its most recent fiscal year\-end, creating significant key\-person and execution risk, and it is a single\-technology, single\-therapeutic\-class company with no diversification if cannabinoid science fails to pan out clinically\.

6\. Financial Overview

| Metric | Value | Period | \|---|---|---| | Total revenue | \$0 | FY ended 8/31/2025 and subsequent quarters | | Cumulative net losses since inception | approximately \$25\.38 million | as of 11/30/2025 | | Net loss | \$\(113,719\) | three months ended 11/30/2025 | | Net loss \(prior\-year comparable quarter\) | \$\(34,352\) | three months ended 11/30/2024 | | G\&A expense | \$64,002 | three months ended 11/30/2025 | | Cash and cash equivalents | \$7,703 | as of 11/30/2025 | | Total assets | \$11,162 | as of 11/30/2025 | | Total liabilities | \$2,584,133 | as of 11/30/2025 | | Stockholders' deficit | \$\(2,572,971\) | as of 11/30/2025 | | Shares outstanding | approximately 553,962,206 | as of 11/20/2025 | | Stock price | approximately \$0\.0076 | as of 2/28/2025 | | Market capitalization \(non\-affiliate float\) | approximately \$251,840 | as of 2/28/2025 | | Estimated cost to complete Phase I/II trials | approximately \$6\.5 million | unfunded as of FY2025 10\-K filing date |

The balance sheet is effectively insolvent on a book basis, with liabilities more than 200 times total assets and cash on hand sufficient for only a very short operating runway absent new financing. The company's small quarterly loss size reflects minimal spending \(essentially no R\&D expense reported and modest G\&A) rather than operating efficiency — spending has been curtailed to a bare\-survival level while the company seeks capital, not because the clinical program is being executed cheaply.

7\. Summary Conclusion

CNBX Pharmaceuticals is a genuine, if extremely small and financially fragile, clinical\-stage oncology biotech built around cannabinoid\-based drug candidates, most notably a sustained\-release formulation for cancer\-related anorexia\-cachexia and a cannabinoid combination candidate for colorectal cancer. It holds real, disclosed intellectual property and early pilot/preclinical data, and it operates through a licensed Israeli research facility with an identifiable, if very thin, scientific team and advisory board. However, the company has no revenue, virtually no cash, a stockholders' deficit, a going\-concern qualification from its auditors, and an unfunded multi\-million\-dollar clinical program standing between it and its next value\-creating milestone. Any investment thesis here is a binary, highly dilutive, high\-risk bet on the company both securing substantial new financing and generating positive human clinical signals in a scientific area \(cannabinoids in oncology\) that mainstream medical bodies still describe as preliminary. Absent a near\-term financing event or partnership, execution risk and dilution risk dominate any potential upside from the pipeline itself.